PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33408297-0	2021	Effects of fenofibrate and its combination with lovastatin on the expression of genes involved in skeletal muscle atrophy, including FoxO1 and its targets.	Lovastatin	48-58	forkhead box O1	Mus musculus	133-138	
33408297-8	2021	When the effect of combination treatment with fenofibrate and lovastatin was investigated, a significant increase in FoxO1 protein levels was observed despite the lack of deterioration of muscle atrophy.	Lovastatin	62-72	forkhead box O1	Mus musculus	117-122	
33408297-9	2021	Collectively, our findings suggest that a high dose of fenofibrate over one week causes skeletal muscle atrophy via enhancement of FoxO1, and combination treatment with fenofibrate and lovastatin may further increase FoxO1 protein level.	Lovastatin	185-195	forkhead box O1	Mus musculus	217-222